Physician profile
Mark Epstein
NPI 1891760005
$7,037.65
in general payments reported to CMS, 2019-2025
32 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $191 · 2021: $138 · 2022: $864 · 2023: $1,902 · 2024: $1,631 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,480 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,480.01 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,303.41 | 2019-2025 | |
| Pfizer INC. | $722.26 | 2019-2025 | |
| Gilead Sciences, INC. | $645.80 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $595.95 | 2022-2025 | |
| Celgene Corporation | $524.57 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.04 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $371.32 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $339.30 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $220.68 | 2019-2025 | Rebyota |
| Organon LLC | $118.76 | 2024-2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $96.47 | 2024-2025 | Iqirvo |
| Stryker Corporation | $68.59 | 2024 | Neptune |
| Ardelyx, INC. | $61.87 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $57.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $49.46 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.32 | 2022 | |
| Intercept Pharmaceuticals, INC. | $43.65 | 2025 | |
| Alnylam Pharmaceuticals INC. | $38.22 | 2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $34.96 | 2025 | Voquezna |
| Celltrion USA INC. | $32.39 | 2025 | Vegzelma |
| Boston Scientific Corporation | $29.96 | 2022 | |
| Alfasigma USA, INC. | $28.80 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $25.60 | 2023 | Fujifilm |
| Merck Sharp & Dohme LLC | $25.42 | 2019-2020 | |
| Micro-Tech Endoscopy USA, INC. | $21.48 | 2025 | Lockado |
| Echosens North America, INC. | $18.46 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.51 | 2023 | Strensiq |
| Aimmune Therapeutics, INC. | $15.26 | 2024 | |
| Ucb, INC. | $15.15 | 2019 | |
| Medtronic, INC. | $14.91 | 2025 | Gi Genius |
| Braintree Laboratories, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.